Drug
Dexmedetomidine
Dexmedetomidine: highest development phase Post-Market, developed by Orion Corporation, Pfizer, Teva. 7 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Orion Corporation, Pfizer, Teva
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dexmedetomidine NCT03813277 | Post-Market | ICU Sedation |
| Dexmedetomidine NCT02004613 | Post-Market | Heart Disease |
| DEXMEDETOMIDINE HYDROCHLORIDE | Approved | |
| Dexmedetomidine NCT00226785 | Phase 3 | Conscious Sedation |
| Dexmedetomidine NCT00479661 | Phase 3 | Continuous Sedation in Initially Sedated Adults in ICU |
| Dexmedetomidine NCT02252523 | Phase 2 | Acute Brain Injuries |
| Dexmedetomidine NCT00747721 | Phase 1 | Pharmacokinetics |
Latest
No recent events.
Follow Dexmedetomidine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.